A planned interim efficacy analysis of the DREAMM-7 head-to-head phase III trial evaluating Blenrep (belantamab mafodotin) as a second-line treatment for relapsed or refractory multiple myeloma produced positive headline results.
Physician-scientists by day, a funk-loving musical troupe by night. You may have seen The CheckPoints—a 13 member cover band with a three-piece brass section and Jim Allison on harmonica—movin’, groovin’, and gettin’ down as a mainstay closing act at ASCO, AACR, or the Society for Immunotherapy of Cancer annual meetings.
